The Next Phase
The CVC is at a pivotal phase in its clinical development of cancer vaccines. More extensive Phase II trials, which include large numbers of patients, are now required to further investigate and validate the CVC preliminary data that correlate an immune response with a clinical response. The major endpoint of these trials is to measure therapeutic efficacy of cancer vaccines.
Initial indications—although from a Phase I trial with small patient numbers—suggest that at least one of the CVC vaccines may impact upon relapse-free survival in melanoma patients. It is now vital that the CVC conduct pivotal Phase II trials to confirm this observation. CRI and LICR are engaged in a campaign to augment their resources to ensure that this happens.